Company: CSTL
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0001628280-25-048254
Chunk: 2

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-11-03
Form: 10-Q
Item: Item 1
Chunk 2
---
,840 28,868 27,659 Diluted29,073 29,401 28,868 28,838 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.2

Table of Contents

CASTLE BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

(UNAUDITED)

(in thousands)

Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Net (loss) income$(501)$2,269 $(21,826)$8,655 Other comprehensive income:Net unrealized gain on marketable investment securities201 645 10 337 Comprehensive (loss) income$(300)$2,914 $(21,816)$8,992 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.3

Table of ContentsCASTLE BIOSCIENCES, INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY(UNAUDITED)(in thousands, except share data)

Common StockAdditionalPaid-inCapitalAccumulatedDeficitAccumulatedOther Comprehensive Income (Loss)TotalStockholders’EquitySharesAmountBALANCE, JANUARY 1, 202427,410,532 $27 $609,477 $(218,371)$136 $391,269 Stock-based compensation expense— — 12,675 — — 12,675 Exercise of common stock options19,066 — 65 — — 65 Issuance of common stock from vested restricted stock units and payment of employees’ taxes44,830 — (474)— — (474)Issuance of common stock under the employee stock purchase plan111,241 1 1,707 — — 1,708 Net unrealized loss on marketable investment securities— — — — (247)(247)Net loss— — — (2,534)— (2,534)BALANCE, MARCH 31, 202427,585,669 $28 $623,450 $(220,905)$(111)$402,462 Stock-based compensation expense— — 13,179 — — 13,179 Exercise of common stock options1,779 — 8 —